- Home
- ACIU vs KINS Comparison
ACIU vs KINS Comparison
Compare ACIU & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIU | KINS |
|---|---|---|
| Founded | 2003 | 1886 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.6M | 284.5M |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ACIU | KINS |
|---|---|---|
| Price | $2.76 | $19.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 194.4K | 75.5K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | N/A | ★ 94.59 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | $706.75 | $24.23 |
| Revenue Next Year | $321.13 | $18.05 |
| P/E Ratio | ★ N/A | $29.30 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $2.10 | $13.38 |
| 52 Week High | $4.00 | $20.90 |
Technical Indicators
Market Signals| Indicator | ACIU | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 40.98 |
| Support Level | $2.57 | $18.68 |
| Resistance Level | $3.00 | $19.42 |
| Average True Range (ATR) | 0.15 | 0.45 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 27.38 | 0.00 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.